Ligand Pharma (LGND) PT Raised to $155 at Benchmark on Remdesivir/Captisol Upside

July 15, 2020 7:02 AM EDT Send to a Friend
Benchmark analyst Robert Wasserman raised the price target on Ligand Pharma (NASDAQ: LGND) to $155.00 (from $138.00) noting the rapid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login